. Author manuscript; available in PMC: 2014 May 13.

Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2009 Jun 12;81(0):213–221. doi: 10.1016/j.plefa.2009.05.015

Table 6. Ongoing Clinical Trials (2008).

Ongoing Trials	PI.
OPAL trial, cognitive decline, age 70-79 MMSE>24, 500 mg DHA + 200 mg EPA (n=800): UK identifier: ISRCTN72331636	Dangour, et al., 2006 (UK) (105)
ADCS trial, mild to mod AD -2 g algal DHA/day for 18 months (n=400), NCT00440050	J. Quinn, OHSU (NIA/ADCS/ Martek)
MIDAS Early memory deficits, 900 mg/d, 6 months (n=465); NCT00278135	K. Yurko-Mauro (Martek Biosciences)
Primary Prevention of cognitive decline in frail elderly, MMSE>24, n=1200, omega 3 (VO137), 800 mg DHA /d 3 years BCT00672685	B. Vellas, University Hospital, Toulouse

Abbreviations: AD Cooperative studies (ADCS); Older People and n-3 Long-chain polyunsaturated fatty acids (OPAL). Mini-mental state examination (MMSE). Memory Improvement with Docosahexaenoic Acid study (MIDAS).